JP7778686B2 - ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤 - Google Patents

ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤

Info

Publication number
JP7778686B2
JP7778686B2 JP2022521134A JP2022521134A JP7778686B2 JP 7778686 B2 JP7778686 B2 JP 7778686B2 JP 2022521134 A JP2022521134 A JP 2022521134A JP 2022521134 A JP2022521134 A JP 2022521134A JP 7778686 B2 JP7778686 B2 JP 7778686B2
Authority
JP
Japan
Prior art keywords
certain embodiments
alkyl
hydrogen
compound
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022521134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552831A (ja
JP2022552831A5 (https=
JPWO2021071965A5 (https=
Inventor
リッカルド ペルフェッティ，
ショーシャナ シェンデルマン，
Original Assignee
アプライド セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプライド セラピューティクス， インコーポレイテッド filed Critical アプライド セラピューティクス， インコーポレイテッド
Publication of JP2022552831A publication Critical patent/JP2022552831A/ja
Publication of JP2022552831A5 publication Critical patent/JP2022552831A5/ja
Publication of JPWO2021071965A5 publication Critical patent/JPWO2021071965A5/ja
Priority to JP2025063234A priority Critical patent/JP2025100631A/ja
Application granted granted Critical
Publication of JP7778686B2 publication Critical patent/JP7778686B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2022521134A 2019-10-08 2020-10-07 ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤 Active JP7778686B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025063234A JP2025100631A (ja) 2019-10-08 2025-04-07 ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962912441P 2019-10-08 2019-10-08
US62/912,441 2019-10-08
PCT/US2020/054607 WO2021071965A1 (en) 2019-10-08 2020-10-07 Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025063234A Division JP2025100631A (ja) 2019-10-08 2025-04-07 ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤

Publications (4)

Publication Number Publication Date
JP2022552831A JP2022552831A (ja) 2022-12-20
JP2022552831A5 JP2022552831A5 (https=) 2023-10-11
JPWO2021071965A5 JPWO2021071965A5 (https=) 2023-10-11
JP7778686B2 true JP7778686B2 (ja) 2025-12-02

Family

ID=75437528

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521134A Active JP7778686B2 (ja) 2019-10-08 2020-10-07 ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤
JP2025063234A Pending JP2025100631A (ja) 2019-10-08 2025-04-07 ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025063234A Pending JP2025100631A (ja) 2019-10-08 2025-04-07 ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤

Country Status (10)

Country Link
US (1) US20220226323A1 (https=)
EP (1) EP4041219A4 (https=)
JP (2) JP7778686B2 (https=)
CN (3) CN114667139B (https=)
AU (1) AU2020363699A1 (https=)
BR (1) BR112022005895A2 (https=)
CA (1) CA3153108A1 (https=)
IL (1) IL291946A (https=)
MX (1) MX2022004270A (https=)
WO (1) WO2021071965A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CN113840825A (zh) 2019-04-01 2021-12-24 应用治疗公司 醛糖还原酶抑制剂
WO2020227430A1 (en) 2019-05-07 2020-11-12 University Of Miami Treatment and detection of inherited neuropathies and associated disorders
WO2024064147A1 (en) * 2022-09-20 2024-03-28 Mayo Foundation For Medical Education And Research Treating congenital disorders of glycosylation
WO2025171282A1 (en) * 2024-02-09 2025-08-14 Landry's Smile, Llc Methods for treating congenital disorders of glycosylation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505040A (ja) 2013-01-16 2016-02-18 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク アルドース還元酵素阻害剤およびその使用
JP2019518779A (ja) 2016-06-21 2019-07-04 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク アルドース還元酵素阻害剤およびその使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008548A2 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20110257233A1 (en) * 2010-03-19 2011-10-20 Sanford-Burnham Medical Research Institute Benzoisothiazolones as inhibitors of phosphomannose isomerase
WO2013123403A1 (en) * 2012-02-15 2013-08-22 Sanford-Burnham Medical Research Institute Theranostics platform and methods of use
EP3275863A1 (en) * 2016-07-29 2018-01-31 Universidad Autónoma de Madrid Compounds for treating congenital disorders of glycosylation
IL272246B2 (en) * 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CA3110162A1 (en) * 2018-08-20 2020-02-27 Maggie's Pearl, Llc Methods for treating congenital disorders of glycosylation
CN113840825A (zh) * 2019-04-01 2021-12-24 应用治疗公司 醛糖还原酶抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505040A (ja) 2013-01-16 2016-02-18 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク アルドース還元酵素阻害剤およびその使用
JP2019518779A (ja) 2016-06-21 2019-07-04 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク アルドース還元酵素阻害剤およびその使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
bioRxiv，2019年09月26日，p.1-47，DOI:10.1101/626697

Also Published As

Publication number Publication date
US20220226323A1 (en) 2022-07-21
MX2022004270A (es) 2022-05-03
IL291946A (en) 2022-06-01
JP2022552831A (ja) 2022-12-20
WO2021071965A1 (en) 2021-04-15
JP2025100631A (ja) 2025-07-03
CN120114457A (zh) 2025-06-10
CA3153108A1 (en) 2021-04-15
BR112022005895A2 (pt) 2022-06-28
CN120093757A (zh) 2025-06-06
AU2020363699A1 (en) 2022-05-26
CN114667139B (zh) 2025-03-28
EP4041219A1 (en) 2022-08-17
CN114667139A (zh) 2022-06-24
EP4041219A4 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
JP7778686B2 (ja) ホスホマンノムターゼ２欠損の処置のためのアルドースレダクターゼ阻害剤
JP7788399B2 (ja) ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤
AU2018307964B2 (en) Compositions and methods for treating galactosemia
RU2858535C2 (ru) Ингибиторы альдозоредуктазы для лечения дефицита сорбитолдегидрогеназы
HK40113967A (en) Compositions and methods for treating galactosemia
RU2830187C2 (ru) Композиции и способы лечения галактоземии
HK40030466A (en) Compositions and methods for treating galactosemia
HK40030466B (en) Compositions and methods for treating galactosemia
BR112020001755B1 (pt) Usos de um inibidor da aldose redutase para o tratamento de galactosemia
US20120302636A1 (en) Method of treating a disorder associated with mtp

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250909

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251119

R150 Certificate of patent or registration of utility model

Ref document number: 7778686

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150